Secukinumab-induced Raynaud's phenomenon: first report in the literature
Yükleniyor...
Dosyalar
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Sage Publications Ltd
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Secukinumab is an IL-17A antagonist that has proven efficacy in the treatment of patients with ankylosing spondylitis (AS) and psoriatic arthritis. Side effects of the drug include infections, skin rashes, and allergic reactions. Raynaud's phenomenon (RP), a vasospastic syndrome and an important feature of different connective tissue diseases, is not an expected finding in AS patients. This article reports the development of secukinumab-related RP in a 35-year-old female patient with AS. Treatment with secukinumab was continued and RP was treated with low-dose aspirin and a calcium-channel blocker.
Açıklama
KOBAK, SENOL/0000-0001-8270-640X
Anahtar Kelimeler
Ankylosing Spondylitis, Raynaud's Phenomenon, Secukinumab
Kaynak
Therapeutic Advances In Drug Safety
WoS Q Değeri
Q2
Scopus Q Değeri
Q2
Cilt
11
Sayı
Künye
Kobak, S. (2020). Secukinumab-induced Raynaud’s phenomenon: first report in the literature. THERAPEUTIC ADVANCES IN DRUG SAFETY, 11. https://doi.org/10.1177/2042098620905976
